16 years ago, China accounted for less than eight percent of the world’s clinical trials. Today it hosts more than any other country. This story – of patient populations, regulatory frameworks, and biotech ecosystems that were once peripheral to global drug development becoming central to it – is being repeated across Asia. But scale and…
InFocus
China now supplies the T-cell engager pipeline reshaping autoimmune disease, but the evidence base hasn’t caught up with the capital. This report tracks eleven direct China-origin transactions worth up to USD 8.6 billion in headline consideration, set against a peer-reviewed human safety and efficacy record of fewer than 90 patients. It explains why deep B-cell…
China’s private biotech financing market showed no signs of cooling in the second quarter of 2026. Excluding public listings, deployment held firm at a broad, venture-driven pace; evidence that the country’s private company pipeline continues to mature well ahead of any eventual listing wave. As this exclusive new Selesta* report shows, China biotech private financing…
For decades, the Middle East carried some of the world’s highest rates of inherited genetic disease, and almost none of the research data needed to treat it. That equation has flipped, fast. Saudi Arabia, the UAE, and Qatar have spent the past decade building sovereign, population-scale genome programs, backed by real capital and paired with…
InFocus: Rare Disease Clinical Development in Hong Kong explores how the city is positioning itself as a globally relevant centre for orphan drug development, drawing on strong clinical infrastructure, accelerated regulatory pathways, and a growing population genomic database. With rare disease therapies now accounting for 35 percent of the global R&D pipeline and over 50…
China’s biotechnology sector has never been harder to ignore. Chinese-origin programmes now account for half of all large-cap pharma licensing deals with upfronts above USD 50 million — a share that has risen from under five percent just five years ago — and the deal activity shows no sign of slowing. In the first quarter…
Lyon has long played a vital role in global health and today stands as one of Europe’s most investable life sciences hubs. While less well-known than Basel, Barcelona, London, or Paris, Lyon stands out through its tight-knit ecosystem of hospitals, research institutes, pharma and medtech manufacturers, biotechs, and service providers. The density and breadth of…
The global landscape for genomic medicine reached an inflection point in late 2025. First-in-human data confirmed that in vivo CAR-T – once a theoretical ambition – is now a biological reality, capable of extraordinary efficacy in patients with hard-to-treat autoimmune diseases. As this exclusive new Selesta* report shows, China has secured a commanding global lead…
This report is the first in PharmaBoardroom’s InFocus: China Biotech Catalysts series, profiling the companies and leaders shaping the next wave of global biotech innovation. PharmaBoardroom has been at the forefront of China’s biopharma boom for almost 20 years, speaking to founders, pharmas and VCs on the ground and doing more than almost any other…
Hong Kong is rapidly transforming from a regional observer into an active force in cell and gene therapy. Long known as a bridge between China and the world, the city is already delivering “Made in Hong Kong” CAR-T therapies under clinical trial conditions and boasts Asia’s first university-led GMP-certified CGT manufacturing centre. With the enticing…
Tremendous scientific and social progress has transformed HIV/AIDS from a death sentence to a manageable chronic condition for many. However, the disease still kills 650,000 people every year with formidable societal, legal, and economic obstacles remaining to realising the ultimate quest of complete eradication. This dedicated InFocus, bringing together key stakeholders in the global HIV…
2023 was a year of transformative change and challenge across the global healthcare and life sciences industries. Drawing on PharmaBoardroom’s exclusive interviews and op-eds from across the world in 2023, our latest report tackles some of the year’s key regional trends. It includes everything from the landmark introduction of drug price negotiations in the US…
